HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Farhad Sedarati Selected Research

Enzyme Inhibitors (Inhibitors, Enzyme)

1/2022Metabolism and Disposition of [14C]Pevonedistat, a First-in-Class NEDD8-Activating Enzyme Inhibitor, after Intravenous Infusion to Patients with Advanced Solid Tumors.
1/2021Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors.
1/2021Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.
1/2019Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors.
5/2015Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Farhad Sedarati Research Topics

Disease

7Neoplasms (Cancer)
05/2022 - 01/2019
3Myelodysplastic Syndromes (Myelodysplastic Syndrome)
11/2022 - 05/2015
3Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
11/2022 - 01/2018
3Postmenopausal Osteoporosis
03/2009 - 01/2008
2Nausea
01/2022 - 01/2019
2Osteoporosis
04/2009 - 03/2009
1Hyperglycemia
01/2022
1Stomatitis
01/2022
1Hematologic Neoplasms (Hematological Malignancy)
01/2021
1Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic)
01/2021
1Rare Diseases (Rare Disease)
01/2021
1Renal Cell Carcinoma (Grawitz Tumor)
11/2020
1Urinary Bladder Neoplasms (Bladder Cancer)
11/2020
1Endometrial Neoplasms (Endometrial Cancer)
11/2020
1Vomiting
01/2019
1Febrile Neutropenia
01/2019
1Thrombocytopenia (Thrombopenia)
01/2019
1Bone Resorption
04/2009
1Osteoporotic Fractures
08/2008
1Chronic Hepatitis C
07/2003
1Hepatitis C
07/2003

Drug/Important Bio-Agent (IBA)

8pevonedistatIBA
11/2022 - 05/2015
7EnzymesIBA
11/2022 - 05/2015
5Enzyme Inhibitors (Inhibitors, Enzyme)IBA
01/2022 - 05/2015
4Ibandronic Acid (Boniva)FDA Link
04/2009 - 01/2008
3Azacitidine (5 Azacytidine)FDA Link
11/2022 - 11/2019
3sapanisertibIBA
05/2022 - 11/2020
2Docetaxel (Taxotere)FDA Link
11/2019 - 01/2019
2Carboplatin (JM8)FDA LinkGeneric
11/2019 - 01/2019
2Paclitaxel (Taxol)FDA LinkGeneric
11/2019 - 01/2019
2GemcitabineFDA Link
11/2019 - 01/2019
2Pharmaceutical PreparationsIBA
01/2019 - 01/2019
2Alendronate (Alendronate Sodium)FDA LinkGeneric
04/2009 - 01/2008
2Diphosphonates (Bisphosphonates)IBA
08/2008 - 01/2008
1Alkaline PhosphataseIBA
01/2022
1Mechanistic Target of Rapamycin Complex 1IBA
11/2020
1Collagen Type I (Type I Collagen)IBA
04/2009
1collagen type I trimeric cross-linked peptideIBA
04/2009
1Interferon-alpha (Interferon Alfa)IBA
07/2003
1RNA (Ribonucleic Acid)IBA
07/2003

Therapy/Procedure

2Therapeutics
04/2009 - 07/2003
1Intravenous Infusions
01/2022
1Intravenous Administration
01/2022
1Investigational Therapies (Experimental Therapy)
01/2021
1Drug Therapy (Chemotherapy)
01/2019